{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:14:23Z","timestamp":1791389663942,"version":"4.3.3"},"reference-count":61,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>We conducted a systematic review and meta\u2010analysis to assess the hepatitis B virus (HBV) screening rate in cancer patients before systemic chemotherapy, aiming to identify those needing antiviral prophylaxis for HBV reactivation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched PubMed, Embase, Scopus, and Google Scholar for relevant studies. The pooled screening rate was estimated using a random effects model. Subgroup analyses were conducted based on malignancy types, chemotherapy regimens, study period, and HBV endemic regions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The meta\u2010analysis included 29 studies from various endemic regions (19 low\u2010endemic, three lower intermediate\u2010endemic, and seven higher intermediate\u2010endemic). These studies encompassed hematologic malignancies (<jats:italic>n<\/jats:italic>\u00a0=\u00a010), solid\u2010organ tumors (<jats:italic>n<\/jats:italic>\u00a0=\u00a04), and combinations (<jats:italic>n<\/jats:italic>\u00a0=\u00a015). Seven studies used rituximab\u2010containing regimens, four did not, and the remaining 11 did not specify chemotherapy regimens. The pooled screening rate was 57% (95% confidence interval [95%CI]: 46%\u201368%, <jats:italic>I<jats:sup>2\u00a0<\/jats:sup><\/jats:italic>=\u00a0100%). Over time, screening rates improved from 37% (95%CI: 23%\u201353%) in 2006\u20132010 to 68% (54%\u201380%) in 2011\u20132015 and 69% (48%\u201384%) in 2016\u20132020. Screening rates were highest at 89% (74%\u201396%) in high endemic countries, followed by 60% (45\u201373%) in lower\u2010intermediate and 49% (34\u201364%) in low\u2010endemic countries. Patients with hematological malignancies had a higher screening rate than those with solid organ tumors, 65% (55%\u201374%) versus 37% (21%\u201357%), respectively. A screening rate was higher in patients receiving rituximab\u2010containing chemotherapy than non\u2010rituximab regimens, 68% (55%\u201379%) versus 45% (27%\u201365%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite existing guidelines, pre\u2010chemotherapy HBV screening rate remains unsatisfactory, with substantial heterogeneous rates globally. These findings underscore the need for effective strategies to align practices with clinical guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.14055","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T17:35:32Z","timestamp":1711042532000},"page":"335-345","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy \u2013 A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"20","author":[{"given":"Soe Thiha","family":"Maung","sequence":"first","affiliation":[{"name":"Division of Gastroenterology Department of Internal Medicine Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society  Bangkok Thailand"},{"name":"Ma Har Myaing Hospital  Yangon Myanmar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natee","family":"Deepan","sequence":"additional","affiliation":[{"name":"Division of Academic Affairs Faculty of Medicine Chulalongkorn University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakanat","family":"Decharatanachart","sequence":"additional","affiliation":[{"name":"Division of Academic Affairs Faculty of Medicine Chulalongkorn University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7965-6921","authenticated-orcid":false,"given":"Roongruedee","family":"Chaiteerakij","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Department of Internal Medicine Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society  Bangkok Thailand"},{"name":"Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology Faculty of Medicine Chulalongkorn University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00487.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06243.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.394"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1121"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29082"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0182"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i28.6484"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2019.87631"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12557"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01618.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8907"},{"key":"e_1_2_10_14_1","unstructured":"WeinbaumCM WilliamsI MastEE et\u00a0al.Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.2008."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3745"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10239-x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_10_20_1","first-page":"372","article-title":"Preferred reporting items for journal and conference abstracts of systematic reviews and meta\u2010analyses of diagnostic test accuracy studies (PRISMA\u2010DTA for abstracts): checklist, explanation, and elaboration","author":"Cohen JF","year":"2021","journal-title":"BMJ"},{"key":"e_1_2_10_21_1","unstructured":"WellsGA SheaB O'ConnellD et\u00a0al.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses: Ottawa Hospital Research Institute. 2021."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.116"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61412-X"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00197-8"},{"key":"e_1_2_10_25_1","unstructured":"TeamRRC.A language and environment for statistical computing [Internet] Vienna. Austria R Foundation for Statistical Computing.2013."},{"issue":"3","key":"e_1_2_10_26_1","first-page":"40","article-title":"meta: an R package for meta\u2010analysis","volume":"7","author":"Schwarzer G","year":"2007","journal-title":"R News"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-201010001-00275"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02332.x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0182"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-201210001-00446"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.970.970"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","unstructured":"LingWHY PangA LeeS\u2010C.Hepatitis B reactivation risk in patients with solid tumors receiving single\u2010agent capecitabine versus doxorubicin\u2010based chemotherapy.2012.","DOI":"10.1200\/jco.2012.30.15_suppl.1575"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-534"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000450"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212447975"},{"issue":"144","key":"e_1_2_10_36_1","first-page":"S","article-title":"Sa1019 incidence of hepatitis B surface antigen and hepatitis B core antibody in a screening population undergoing chemotherapy","volume":"5","author":"Sammons MK","year":"2013","journal-title":"Gastroenterology"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i6.923"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116978"},{"key":"e_1_2_10_39_1","first-page":"1","article-title":"Outcomes of the implementation of the computer\u2010assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis","volume":"1","author":"Sanagawa A","year":"2015","journal-title":"J Pharma Health Care Sci"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27843"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-016-4118-1"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2502-0"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-016-0995-8"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31834-2"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30775"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13740"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4850-1"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2018.0111"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59476-4"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01655-4"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.34172\/aim.2020.111"},{"key":"e_1_2_10_52_1","first-page":"1","article-title":"Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk\u2010based approach?","author":"Reynolds G","year":"2021","journal-title":"Support Care Cancer"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.657109"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220913095"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14685"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06465.x"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2007.01479.x"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-011-9279-6"},{"key":"e_1_2_10_61_1","unstructured":"US Food and Drug Administration. 2006. Available from: Accessed Jun 19 2011http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm150758\/htm"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq583"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:34:53Z","timestamp":1718602493000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/ajco.14055"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14055","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"2023-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}